Synergy rockets on Phase III constipation data
This article was originally published in Scrip
Executive Summary
Positive topline results from the first of two pivotal Phase III trials of Synergy Pharmaceuticals' chronic idiopathic constipation drug plecanatide have sent the company's share price soaring.